IRLAB Therapeutics

We are pleased to announce that the already strong patent protection for mesdopetam in China is now being extended to include the salt form of the active ingredient used in the clinical development. This extended protection can potentially extend the market exclusivity of mesdopetam towards the mid 2040s, significantly increasing the value of the drug candidate," says Kristina Torfgård, CEO, IRLAB.

Mesdopetam has a significant clinical potential to address the extensive unmet medical needs associated with Parkinson's disease. The drug candidate is intended to treat people with Parkinson's who develop levodopa-induced dyskinesias (LIDs), which affect more than 30 percent of all people living with the disease. This equates to more than 1.5 million affected individuals in the eight major markets worldwide.

The newly granted patent covers the salt form of the drug used in ongoing clinical development and expires in the 2040s. In the event of a possible extension of the patent period (Patent Term Extension; PTE), the exclusivity could potentially extend towards the mid 2040s. Mesdopetam has previously been granted a substance patent, in all major markets globally and the new patent provides added protection and extended exclusivity in most of the major markets such as China, the USA, Europe and Japan.